Cardiovascular autonomic neuropathy in children and adolescents with type 1 diabetes

Cardiovascular autonomic neuropathy and its associated factors in children and adolescents with type 1 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20251110001

Enrollment

120

Registered

2025-11-10

Start date

2026-01-05

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prevalence of cardivascular autonomic neuropathy in Thai children and adolescents with type 1 diabetes Cardivascular autonomic neuropathy Arterial stiffness Children and adolescents with type 1 diabetes

Interventions

Children with T1D

Diagnostic

Eligibility

Sex/Gender

All

Age

8 Years to 24 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosed with type 1 diabetes mellitus according to the American Diabetes Association criteria before the age of 18 years 2. Duration of diabetes >1 year 3. Regularly follow up at KKU or KKH hospital for at least 1 year before enrollment

Exclusion criteria

Exclusion criteria: 1. Incomplete medical records 2. Serum creatinine more than 1.5 mg/dL 3. HbA1c more than 13% 4. Hypertension, defined as systolic or diastolic blood pressure above 95th percentile for age, sex, and height, or more than 130/80 mmHg in children aged equal or above 13 years 5. Presence of conditions or diseases affecting heart rate variability (HRV) or HRV measurement, such as heart failure, arrhythmias (including atrial fibrillation, atrial flutter, premature atrial contraction, premature ventricular contraction, junctional or ventricular rhythm, 2nd/3rd degree AV block, sinus bradycardia, sinus pause/arrest) 6. Having a pacemaker and being totally pacemaker-dependent 7. Use of ACE inhibitors, ARBs, ARNIs, SGLT2 inhibitors, GLP-1 agonists, or calcium channel blockers within the past 3 months 8. Conditions or diseases affecting pulse wave velocity (PWV) (except dyslipidemia), such as acute high fever within the past 2 weeks, diabetic ketoacidosis (DKA) within the past 2 weeks, or severe hypoglycemia (plasma glucose less than 55 mg/dL) within the past 3 days 9. Use of medications that affect PWV and HRV, including systemic corticosteroids, immunosuppressants, non-insulin antidiabetic drugs, atypical antipsychotics, beta-blockers, digitalis, theophylline, tricyclic antidepressants, anti-arrhythmic drugs, or atropine within the past 1 month

Design outcomes

Primary

Measure	Time frame
Heart rate variability Baseline ECG	—

Secondary

Measure	Time frame
Heart rate variability Baseline Polar H10,Carotid-femoral pulse wave velocity Baseline Applanation tonometry	—

Countries

Thailand

Contacts

Public ContactPattara Wiromrat

Khon Kaen University

patwiro@kku.ac.th66867168485

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026